Thermo Fisher Scientific Inc (NYSE:TMO) insider Daniel P. Shine sold 2,026 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total value of $366,645.22. Following the completion of the transaction, the insider now directly owns 20,682 shares in the company, valued at $3,742,821.54. The transaction was disclosed in a filing with the SEC, which is available at this link.

Thermo Fisher Scientific Inc (NYSE TMO) traded down 0.64% during midday trading on Friday, hitting $185.94. The stock had a trading volume of 1,146,090 shares. The firm has a 50-day moving average of $177.22 and a 200 day moving average of $168.21. The firm has a market capitalization of $72.54 billion, a P/E ratio of 32.39 and a beta of 1.06. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $188.76.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The company had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.03 earnings per share. On average, equities analysts forecast that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/01/thermo-fisher-scientific-inc-tmo-insider-daniel-p-shine-sells-2026-shares.html.

Several research firms have recently weighed in on TMO. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a report on Tuesday, August 1st. Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Deutsche Bank AG set a $200.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Saturday, June 10th. BidaskClub cut Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Barclays PLC reissued an “overweight” rating and set a $200.00 price target (up from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th. One equities research analyst has rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus target price of $189.50.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Independent Portfolio Consultants Inc. increased its position in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares in the last quarter. Sharkey Howes & Javer increased its position in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares in the last quarter. Beacon Trust Co. increased its position in Thermo Fisher Scientific by 0.6% in the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock worth $341,000 after buying an additional 12 shares in the last quarter. Dumont & Blake Investment Advisors LLC increased its position in Thermo Fisher Scientific by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock worth $849,000 after buying an additional 15 shares in the last quarter. Finally, Reinhart Partners Inc. increased its position in Thermo Fisher Scientific by 0.6% in the second quarter. Reinhart Partners Inc. now owns 3,430 shares of the medical research company’s stock worth $598,000 after buying an additional 20 shares in the last quarter. Institutional investors own 83.52% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.